2021
DOI: 10.1021/jasms.1c00075
|View full text |Cite
|
Sign up to set email alerts
|

Investigation of Cysteine Modifications in Recombinant Protein Tetanus Toxoid Heavy Chain Fragment C

Abstract: For conjugated HIV-1 fusion peptide vaccine development, recombinant Tetanus toxoid heavy chain fragment C (rTTHC) was applied as a carrier protein to boost peptide immunogenicity. Understanding the characteristics of rTTHC is the first step prior to the peptide conjugation. A comprehensive mass spectrometry (MS) characterization was performed on E. coli expressed rTTHC during its purification process. Intact mass along with peptide mapping analysis discovered the existence of three cysteine modification forms… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 16 publications
0
1
0
Order By: Relevance
“…Likewise, disulfide bond shuffling is also frequently discussed with regards to proteins derived from E.coli cells because E.coli lack an endoplasmic reticulum. For proteins produced in mammalian cell lines, such as the CHO cell lines used to produce rituximab and bevacizumab, the endoplasmic reticulum acts a center for disulfide bond modulation, checking for the proper formation of bonds ( Zhang et al, 2011 ; Cai et al, 2021 ). Nevertheless, IgG1 therapeutics are not fully immune to disulfide bond shuffling.…”
Section: Introductionmentioning
confidence: 99%
“…Likewise, disulfide bond shuffling is also frequently discussed with regards to proteins derived from E.coli cells because E.coli lack an endoplasmic reticulum. For proteins produced in mammalian cell lines, such as the CHO cell lines used to produce rituximab and bevacizumab, the endoplasmic reticulum acts a center for disulfide bond modulation, checking for the proper formation of bonds ( Zhang et al, 2011 ; Cai et al, 2021 ). Nevertheless, IgG1 therapeutics are not fully immune to disulfide bond shuffling.…”
Section: Introductionmentioning
confidence: 99%